Interaction of cytochrome P450 3A inhibitors with P-glycoprotein

Journal of Pharmacology and Experimental Therapeutics

Volumn 303, Issue 1, 2002, Pages 323-332

  Yasuda, Kazuto ^a   Lan, Lu Bin ^b   Sanglard, Dominique ^a   Furuya, Katryn ^c   Schuetz, John D ^a   Schuetz, Erin G ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; BROMOCRIPTINE; CALCEIN; CLOTRIMAZOLE; CYCLOSPORIN A; CYTOCHROME P450 3A; CYTOCHROME P450 INHIBITOR; DIHYDROERGOCRISTINE; DIHYDROERGOCRYPTINE; DIHYDROERGOTAMINE; ERGOCORNINE; ERGOCRISTINE; ERGOCRYPTINE; ERGOMETRINE; ERGOT ALKALOID; ERGOTAMINE; ERYTHROMYCIN; FLUCONAZOLE; GLYCOPROTEIN P; KETOCONAZOLE; MACROLIDE; MICONAZOLE; PEPTIDE DERIVATIVE; PYRROLE DERIVATIVE; RESERPINE; TROLEANDOMYCIN; UNINDEXED DRUG; VINBLASTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL POLARITY; CELL STRAIN; DRUG PROTEIN BINDING; DRUG TRANSPORT; GENE EXPRESSION; ISOTOPE LABELING; KIDNEY EPITHELIUM; MALE; MEMBRANE TRANSPORT; MICROFLUOROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BIOLOGICAL TRANSPORT; CELL LINE; CELLS, CULTURED; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DIHYDROERGOCRYPTINE; DRUG INTERACTIONS; ENZYME INHIBITORS; FLUCONAZOLE; HUMANS; MICE; MICE, KNOCKOUT; MICROSOMES, LIVER; OXIDOREDUCTASES, N-DEMETHYLATING; P-GLYCOPROTEIN; RECOMBINANT PROTEINS; RESERPINE; SWINE; TISSUE DISTRIBUTION; TRANSFECTION; VINBLASTINE;

EID: 0036784516     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.037549     Document Type: Article

References (33)

1. Albengres E, Le Louet H, and Tillement JP (1998) Systemic antifungal agents drug interactions of clinical significance. Drug Safety 18:83-97.
2. Beck WT (1991) Modulators of P-glycoprotein-associated multidrug resistance, in Molecular and Clinical Advances in Anticancer Drug Resistance (Ozols RF ed) pp 151-170, Kluwer Academic Publishers, Boston.
3. Bosch I, Crankshaw CL, Piwnica-Worms D, and Croop JM (1997) Characterization of functional assays of multidrug resistance P-glycoprotein transport activity. Leukemia 11:1131-1137.
4. Brown PC, Thorgeirsson SS, and Silverman JA (1993) Cloning and regulation of the rat mdr2 gene. Nucleic Acids Res 21:3885-3891.
5. Campana C, Regazzi MB, Buggia I, and Mariadelfina M (1996) Clinically significant drug interactions with cyclosporin. Clin Pharmacokinet 30:141-179.
6. de Mey C, Althaus M, Ezan E, and Retzow A (2001) Erythromycin increases plasma concentrations of α-dihydroergocryptine in humans. Clin Pharmacol Ther 70:142-148.
7. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz E, Lan L, Yasuda K, Shepard RL, Winter MA, Schuetz JD, et al. (2002) Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol 61:964-973.
8. i values and impact of CYP3A5 expression. Drug Metab Dispos 27:180-187.
9. Khan EU, Reichel A, Begley DJ, Roffey SJ, Jezequel SG, and Abbott NJ (1998) The effect of drug lipophilicity on P-glycoprotein mediated colchicine efflux at the blood-brain barrier. Int J Clin Pharmacol Ther 36:84-86.
10. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, et al. (1999) Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharmacol Res 16:408-414.
11. Korneyev AY and Cincotta AH (1996) Identification of hepatic, non-monoamine, dihydroergocryptine binding sites with significant gender differences. Life Sci 58:241-248.
12. Lampidis TJ, Kolonias D, Podona T, Israel M, Safa AR, Lothstein L, Savaraj N, Tapiero H, and Priebe W (1997) Circumvention of Pgp MDR as a function of anthracycline lipophilicity and charge. Biochemistry 36:2679-2685.
13. Lan L-B, Ayesh S, Lyubimov E, Pashinsky I, and Stein WD (1996) Kinetic parameters for reversal of the multidrug pump as measured for drug accumulation and cell killing. Cancer Chemother Pharmacol 38:181-190.
14. Liminga G, Nygren P, and Larsson R (1994) Microfluorometric evaluation of calcein acetoxymethyl ester as a probe for P-glycoprotein-mediated resistance: effects of cyclosporin A and its nonimmunosuppressive analogue SDZ PSC 833. Exp Cell Res 212:291-296.
15. Miyama T, Takanaga H, Matsuo H, Yamano K, Yamamoto K, Iga T, Naito M, Tsuruo T, Ishizuka H, Kawahara Y, et al. (1998) P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier. Antimicrob Agents Chemother 42: 1738-1744.
16. Niedhart M (1996) Synergism between long-acting bromocriptine microcapsules and cyclosporine A in the prevention of various autoimmune diseases in rats. Experientia 52:892-899.
17. Oude Elferink RPJ and Zadina J (2001) MDR1 P-glycoprotein transports endogenous opioid peptides. Peptides 22:2015-2020.
18. Peyronneau M-A, Delaforge M, Riviere R, Renaud J-P, and Mansuy D (1994) High affinity of ergotpeptides for cytochromes P4503A. Eur J Biochem 223:947-956.
19. Phung-Ba V, Warnery A, Scherman D, and Wils P (1995) Interaction of pristinamycin IA with P-glycoprotein in human intestinal epithelial cells. Eur J Pharmacol 288:187-192.
20. Pichard L, Fabre I, Fabre G, Domergue J, Saint Aubert B, Mourad G, and Maurel P (1990) Cyclosporin A drug interactions: screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 18:595-606.
21. Salphati L and Benet LZ (1998) Effects of ketocenazole on digoxin absorption and disposition in rat. Pharmacology 56:308-313.
22. Schinkel AH, Smit JJM, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CAAM, van der Valk MA, Robanus-Maandag EC, te Riele HPJ, et al. (1994) Disruption of the mouse mdr1a P-glyceprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502.
23. Schinkel AH, Wagenaar E, van Deemter L, Mol C, and Borst P (1995) Absence of the mdr1a p-glycoprotein in mice affects tissue distribution and pharmacokineties of dexamethasone, digoxin and cyclosporin A. J Clin Investig 96:1698-1705.
24. Schuetz JD and Schuetz EG (1993) Extracellular matrix regulation of multidrug resistance in primary monolayer cultures of adult rat hepatocytes. Cell Growth Differ 4:31-40.
25. Schuetz EG, Yasuda K, Arimor K, and Schuetz JD (1998) Human MDR1 and mouse mdr1a P-glycoprotein alter the cellular retention and disposition of erythromycin, but not of retinoic acid or benzo(a)pyrene. Arch Biochem Biophys 350:340-347.
26. Shapiro AB and Ling V (1997) Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur J Biochem 250:130-137.
27. Shapiro AB, Fox K, Lam P, and Ling V (1999) Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Eur J Biochem 259:841-850.
28. Stein WD (1997) Kinetics of the multidrug transporter (P-glycoprotein) and its reversal. Pharmacol Rev 77:545-590.
29. Thummel KE and Wilkinson GR (1998) In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 38:389-430.
30. Tiberghien F and Loor F (1996) Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. Anticancer Drugs 7:568-578.
31. von Rosenteil NA and Adam D (1995) Macrolide antibacterials. Drug interactions of clinical significance. Drug Safety 13:105-122.
32. Wandel C, Kim RB, Kajiji S, Guengerich FP, Wilkinson GR, and Wood AJJ (1999) P-glycoprotein and cytochrome P-4503A inhibition: dissociation of inhibitory potencies. Cancer Res 59:3944-3948.
33. Zhang YC, Hsieh YS, Izumi T, Lin ET, and Benet LZ (1998) Effects of keteconazole on the intestinal metabolism, transport and oral bioavailability of KO2, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P4503A, P-glycoprotein dual substrate, in male Sprague-Dawley rats. J Pharmacol Exp Ther 287:246-252.